

**Abstract:**

Teaching Health Centers in Primary Care: A Scoping Review

Jennifer Nguyen, MD PGY 3 Resident, Northwestern McGaw Family Medicine at Humboldt Park

**Purpose:**

The 340b Program is a federal program that provides medications to patients that are uninsured or low-resourced predominantly receiving services at Federally Qualified Health Centers (FQHCs) in the outpatient setting. This study looks at the impact of manufacturer-led formulary changes in 2022 on diabetes outcomes, primarily glycemic control and secondarily renal function, in patients of Erie Family Health Center, a Chicago-based FQHC.

**Methods:**

We identified patients who were affected by formulary changes in diabetes medications, namely sitagliptin/metformin (Janumet) and sitagliptin (Januvia), with the assistance of Erie Family Health Center's Pharmacy Team. Patients were included in the study if they had A1c values, creatinine values, glomerular filtration rates, and urine microalbumin levels (the variables of interest) checked at least once one year before and after they were scheduled to run out of their previously covered medication. Data was obtained through patients' EMR charts and recorded in REDCap.

**Results and Conclusion:**

The study is still in progress. The hypothesis is that patients affected by these formulary changes of these critical medications had negative impacts on their diabetes outcomes due to the limitations placed on their medication options.